Allogene Therapeutics Raises $325M in Series E

Allogene Therapeutics has successfully raised $325M in a Series E at a $3.9B valuation led by TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.

Company Overview

Allogene Therapeutics is a Biotech company headquartered in 210 East Grand Avenue, South San Francisco, CA 94080, founded in 2017 with 700+ employees.

Allogeneic CAR T therapy developer

Fundraising Details

Amount Raised: $325M
Round Type: Series E
Valuation: $3.9B
Date: 2024-04-15
Investors: TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California

About Allogene Therapeutics

Allogeneic CAR T therapy developer The company is positioned in the Biotech sector, serving a growing market with innovative solutions.

Key Information

Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
Founded: 2017
Team Size: 700+
Industry: Biotech

What This Means

This funding round demonstrates strong investor confidence in Allogene Therapeutics's vision and execution. The capital will likely be used to:

Scale Operations: Expand the team and operational capacity
Product Development: Enhance existing products and develop new features
Market Expansion: Enter new markets and strengthen presence in existing ones
Technology Investment: Invest in infrastructure and technology capabilities

Industry Context

The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Allogene Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.

Valuation Milestone

Reaching a $3.9B valuation marks an important milestone for Allogene Therapeutics, positioning the company among notable players in the Biotech industry.

Looking Ahead

With this new capital, Allogene Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.

This fundraising news was reported on 2024-04-15. For more information about Allogene Therapeutics, visit their headquarters at 210 East Grand Avenue, South San Francisco, CA 94080.